Mineralys Therapeutics, Inc. MLYS Income Statement
| FY'25 | FY'24 | FY'23 | ||
|---|---|---|---|---|
| $132.01M-21.7% | $168.58M+140% | $70.36M+168% | ||
| $38.6M+62.0% | $23.82M+66.6% | $14.3M+173% | ||
| $170.6M-11.3% | $192.4M+127% | $84.66M+169% | ||
| -$170.6M+11.3% | -$192.4M-127% | -$84.66M-169% | ||
| $15.95M+9.4% | $14.59M+14.4% | $12.76M+661% | ||
| $15.95M+9.3% | $14.59M+14.4% | $12.76M+659% | ||
| -$154.65M+13.0% | -$177.81M-147% | -$71.9M-141% | ||
| -$2.32+36.3% | -$3.64-80.2% | -$2.02+65.1% | ||
| -$170.55M+11.3% | -$192.36M-127% | -$84.66M— | ||
| -$170.6M+11.3% | -$192.4M-127% | -$84.66M-169% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Mineralys Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Mineralys Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.